| | | Colistin dosing | | | | 9 MIU daily | 3 MIU TDS | value |
| | Gender | | | | | Male, n (%) | 11 (64.7%) | 12 (66.7%) | 0.999 | | Female, n (%) | 6 (35.3%) | 6 (33.3%) | | | Age (mean, range) | 45.6 ± 18.29 (20–75) | 54.6 ± 14.61 (26–78) | 0.115 | | Comorbidity | | | | | Diabetes mellitus | 2 (11.8%) | 5 (27.8%) | 0.402 | | HTN | 5 (29.4%) | 6 (33.3%) | 0.999 | | Cerebral infarct or hemorrhage | 2 (11.8%) | 4 (22.2%) | 0..658 | | Other CNS complications | 1 (5.9%) | 3 (16.7%) | 0.603 | | Heart dysfunction | 0 (0%) | 1 (5.3%) | 0.999 | | Solid organ transplantation | 3 (14.7%) | 4 (22.2%) | 0.999 | | Chronic pulmonary disease | 1 (5.9%) | 1 (5.3%) | 0.999 | | Admission diagnosis | | | | | Cerebral infarct or hemorrhage | 6 (35.3%) | 8 (44.4%) | | | Other CNS complications | 6 (35.3%) | 5 (27.8%) | | | Trauma | 1 (5.9%) | 1 (5.6%) | 0.986 | | GI bleeding | 1 (5.9%) | 1 (5.6%) | | | HTN crisis | 3 (17.6%) | 3 (16.7%) | | | APACHE II score, mean ± SD | 21 ± 4.96 | 20.4 ± 4.99 | 0.723 | | CMS duration, median days (IQR) | 14 (4) | 14 (10) | 0.369 | | ICU duration, median days (IQR) | 31 (17) | 29.5 (30) | 0.859 | | ICU mortality, all days, n (%) | 6 (35.29%) | 4 (22.22%) | 0.392 | | Source of infection | | | 0.581 | | BSI, n (%) of cases | 3 (17.6%) | 2 (11.1%) | | | VAP, n (%) of cases | 14 (82.4%) | 16 (88.9%) | | | Combination with other antibiotics | | | | | Aminoglycosides | 3 | 6 | | | Beta-lactams | 3 | 2 | | | Quinolones | 3 | 3 | | | Carbapenems | 8 | 7 | |
|
|
APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CMS, colistimethate sodium; ICU, intensive care unit; MIU, million international units; SD, standard deviation; CNS, central nervous system, CVA, cerebral vascular accident; GI, gastrointestinal; HTN, hypertension; VAP, ventilator-associated pneumonia. MIN; minimum, MAX; maximum. IQR; interquartile range.
|
